JULY 17, 2020 - "With a foundation in our profitable pharmaceutical business, Orexo has been able to invest and act on opportunities where we are uniquely positioned to help millions of people suffering from mental illness"
SEPTEMBER 1 2020 - Orexo and Lyfebulb today announce the finalists and jury for the 2020 Innovation Challenge in substance use disorder, with the ultimate goal to seek novel digital solutions to address unmet needs in supporting successful, long-term recovery from alcohol and opioid use disorders.
JULY 16 2020 - In Q2, the focus was to prepare for an accelerated launch of the digital offering and the pipeline advanced as OX125 showed strong study results. According to expectations, ZUBSOLV® volume declined YoY, due to the changed position at United Health Group. In parallel, ZUBSOLV® continued to show strong profit and cash contribution, which partially compensated for the increased investments in DTx and RnD.
JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.